Vol. 19/No. 9

Herman D. Suit, MD, MSc, PhD, a leader in the field of radiation oncology whose innovations lessened the need for radical surgery and improved outcomes for patients, was honored in the Radiation Oncology category with a 2017 Giants of Cancer Care® award.

The phase IIb UNITY-NHL clinical trial is exploring the novel drug umbralisib as monotherapy or as part of a doublet or a triplet. The doublet includes ublituximab and the triplet includes ublituximab and bendamustine.

Since 2008, 423 individual cancer treatment sites have closed and another 658 community cancer centers were acquired by or became affiliated with hospitals.

Marcus Neubauer, MD, discusses the tools needed for a practice to succeed with the Oncology Care Model.

A panel of experts discuss the latest developments in the treatment of patients with HER2-positive breast cancer.

Components of the T-cell receptor complex, which links antigen recognition with T-cell activity and effector function, are being exploited for several types of cancer immunotherapy.

Amid an explosion of innovation and discovery in the oncology field, researchers are finding it increasingly difficult to recruit enough patients for clinical trials.

Mark Burkard, MD, PhD, discusses an unusual study launched at the University of Wisconsin.

It is quite difficult for those not directly involved in the complex world of academic medicine to understand fully the process of individual professional advancement and the values that organizations place on the components required for achieving and maintaining tenure.